Patients with both Langerhans cell histiocytosis and Crohn's disease highlight a common role of interleukin-23.

患有朗格汉斯细胞组织细胞增生症和克罗恩病的患者凸显了白细胞介素-23的共同作用

阅读:9
作者:Kvedaraite Egle, Lourda Magda, Han HongYa, Tesi Bianca, Mitchell Jenée, Ideström Maja, Mouratidou Natalia, Rassidakis George, von Bahr Greenwood Tatiana, Cohen-Aubart Fleur, Jädersten Martin, à kefeldt Selma Olsson, Svensson Mattias, Kannourakis George, Bryceson Yenan T, Haroche Julien, Henter Jan-Inge
AIM: To present the first case series of patients with Langerhans cell histiocytosis (LCH) also affected by Crohn's disease (CD), both of which are granulomatous diseases, and in LCH investigate the role of interleukin (IL)-23, which is a well-described disease mediator in CD. METHODS: A case series of three patients with LCH and CD were described; a cohort of LCH patients (n = 55) as well as controls (n = 55) were analysed for circulating IL-23 levels; and the relation between the percentage of LCH cells in lesions and circulating IL-23 levels was analysed in seven LCH patients. RESULTS: Differential diagnostic challenges for these two granulomatous diseases were highlighted in the case series, and it took up to 3 years to diagnose CD. Elevated IL-23 levels were found in LCH patients. The amount of lesional LCH cells correlated with the levels of circulating IL-23. CONCLUSION: Both CD and LCH should be considered in patients with inflammatory gastrointestinal involvement. The IL-23 pathway is a common immunological trait between these two granulomatous diseases.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。